Emmaus Life Sciences, Inc. discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Market Cap | 63.963 Million | Shares Outstanding | 49.584 Million | Avg 30-day Volume | 30.405 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.06 |
Price to Revenue | 0.5442 | Debt to Equity | -0.7796 | EBITDA | -4.683 Million |
Price to Book Value | 0.0 | Operating Margin | -65.45870000000001 | Enterprise Value | 4.015 Million |
Current Ratio | 0.154 | EPS Growth | -11.743 | Quick Ratio | 0.064 |
1 Yr BETA | 0.6037 | 52-week High/Low | 0.0 / | Profit Margin | -114.2571 |
Operating Cash Flow Growth | -2729.3269 | Altman Z-Score | -9.4506 | Free Cash Flow to Firm | 13.557 Million |
Please sign in first
2 Million total shares from 1 transactions
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
2,000,000 | 2023-01-18 | 2 | |
NIIHARA YUTAKA CHAIRMAN AND CEO |
|
0 | 2023-01-12 | 18 |
LEE WILLIS C COO |
|
500,000 | 2023-01-12 | 6 |
NAGASAKI YASUSHI CFO |
|
150,000 | 2023-01-12 | 1 |
|
100,000 | 2023-01-12 | 2 | |
SEKULICH GEORGE CIO & SVP |
|
100,000 | 2023-01-12 | 1 |
STARK CHARLES WILLIAM SVP, CLINICAL DEVELOPMENT |
|
100,000 | 2023-01-12 | 1 |
|
100,000 | 2023-01-12 | 2 | |
|
18,161 | 2022-01-06 | 0 | |
|
42,358 | 2022-01-03 | 0 | |
|
0 | 2020-03-25 | 0 | |
|
0 | 2019-07-17 | 0 | |
TRAN LAN T. CHIEF ADMINISTRATIVE OFFICER |
|
26,562 | 2019-07-17 | 0 |
|
518,367 | 2019-07-17 | 0 | |
SHERWOOD JOSEPH CHARLES III CHIEF FINANCIAL OFFICER |
|
0 | 2019-07-17 | 0 |
D'AMBROSIO DONALD ERIC CHIEF FINANCIAL OFFICER |
|
0 | 2019-06-25 | 0 |
|
1,117,925 | 2019-05-23 | 0 | |
|
211,539 | 2019-05-08 | 0 | |
HERGUTH PATRICK CHIEF EXECUTIVE OFFICER |
|
0 | 2018-12-12 | 0 |
CARPENTER GEORGE C IV CHIEF INNOVATION OFFICER |
|
0 | 2018-12-12 | 0 |
|
97,110 | 2018-10-08 | 0 | |
|
0 | 2018-10-08 | 0 | |
|
1,056,474 | 2018-10-08 | 0 | |
|
126,627 | 2018-10-08 | 0 | |
|
236,345 | 2016-11-30 | 0 | |
|
No longer subject to file | 2016-11-01 | 0 | |
BUCK PAUL CHIEF FINANCIAL OFFICER |
|
0 | 2016-11-01 | 0 |
|
No longer subject to file | 2016-11-01 | 0 | |
|
167,781 | 2016-11-01 | 0 | |
|
0 | 2015-12-23 | 0 | |
|
6,069,376 | 2014-07-11 | 0 | |
|
0 | 2013-05-23 | 0 | |
DARKOCH MICHAEL EXECUTIVE VP & CMO |
|
53,333 | 2012-11-28 | 0 |
|
0 | 2011-02-28 | 0 | |
|
1,707,500 | 2010-11-03 | 0 | |
|
1,441,166 | 2010-11-03 | 0 | |
|
0 | 2010-03-03 | 0 | |
|
0 | 2010-03-03 | 0 | |
|
0 | 2010-03-03 | 0 | |
HOFFMAN DANIEL A PRESIDENT AND CMO |
|
0 | 2010-03-03 | 0 |
|
8,890,795 | 2009-08-26 | 0 | |
|
3,632,711 | 2009-06-30 | 0 | |
|
3,632,711 | 2009-06-30 | 0 | |
LUCE BRADLEY V.P. FINANCE & CONTROLLER |
|
No longer subject to file | 2008-09-17 | 0 |
HERTZ HORACE CFO |
|
651,250 | 2007-08-08 | 0 |
PHILLIPS SILAS A CEO, CFO AND SECRETARY |
|
322,674 | 2006-07-18 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-01-20 11:40:58 -0500 | 2023-01-18 | P | 2,000,000 | $0.50 | a | 2,000,000 | direct | |||||||||
NIIHARA YUTAKA - Director - Officer - > 10% Owner CHAIRMAN AND CEO |
2023-01-17 13:59:20 -0500 | 2023-01-12 | A | 7,500,000 | $4.50 | a | 0 | direct | ||||||||
2023-01-17 14:27:49 -0500 | 2023-01-12 | A | 750,000 | $4.50 | a | 750,000 | direct | |||||||||
2023-01-17 14:29:30 -0500 | 2023-01-12 | A | 150,000 | $4.50 | a | 150,000 | direct | |||||||||
2023-01-17 14:31:02 -0500 | 2023-01-12 | A | 100,000 | $4.50 | a | 100,000 | direct | |||||||||
2023-01-17 14:32:23 -0500 | 2023-01-12 | A | 100,000 | $4.50 | a | 100,000 | direct | |||||||||
2023-01-17 14:34:14 -0500 | 2023-01-12 | A | 100,000 | $4.50 | a | 100,000 | direct | |||||||||
2023-01-17 14:35:49 -0500 | 2023-01-12 | A | 100,000 | $4.50 | a | 100,000 | direct | |||||||||
2023-01-17 14:36:53 -0500 | 2023-01-12 | A | 100,000 | $4.50 | a | 100,000 | direct | |||||||||
2023-01-19 17:54:15 -0500 | 2023-01-12 | A | 500,000 | $4.50 | a | 500,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 22:15:03 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 21:45:03 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 21:15:03 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 20:45:06 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 20:15:04 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 19:45:03 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 19:15:04 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 18:45:03 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 18:15:03 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 17:45:03 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 17:15:04 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 16:45:04 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 16:15:03 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 15:45:03 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 15:15:03 UTC | -10.6248 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 14:45:04 UTC | -10.8748 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 14:15:04 UTC | -10.8748 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 13:45:03 UTC | -10.8748 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 13:15:03 UTC | -10.8748 | 15.1948 | 400000 |
EMMAUS LIFE SCIENCES INC EMMA | 2023-02-03 12:45:03 UTC | -10.8748 | 15.1948 | 400000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|